

Receipt date: 03/17/2006

10554036 - GAU: 1626

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

of	2	4
----	---	---

**Complete if Known**

Application Number	10/554,036
Filing Date	October 20, 2005
First Named Inventor	Besidski
Art Unit	Unknown
Examiner Name	Unknown STOCKTON
Attorney Docket Number	101023-1P IIS

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	1
		Country Code*Number*Kind Code (if known)	MM-DD-YYYY			
	A4	EP 0599382	06-01-1994	Eastman Kodak Company		
	A5	EP 0599384	06-01-1994	Eastman Kodak Company		
	A6	WO 94/14801	07-07-1994	Smithkline Beecham PLC		
	A7	WO 01/12188	02-22-2001	Pharmacia & Upjohn et al.		
	A8	WO 02/090326	11-14-2002	Smithkline Beecham PLC		
	A9	WO 02/42273	05-30-2002	Bristol-Myers Squibb Co.		

Examiner Signature	/Laura L. Stockton/	Date Considered	12/04/2008
-----------------------	---------------------	--------------------	------------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes or USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is not required by 35 USC 1.122 and 37 CFR 1.14. The collection is estimated to take 2 hours to complete, including gathering, reviewing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LLS/

10554036 - GAU: 1626

PTO/SB/08A (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
No collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/554,036
Filing Date	October 20, 2005
First Named Inventor	Besidski
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	101023-1P US

Sheet 2 of 4

## U. S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	†
		Country Code* Number * Kind Code* (if known)	MM-DD-YYYY			
	A10	WO 03/014064	02-20-2003	Bayer Aktiengesellschaft		
	A11	WO 03/037274	05-08-2003	icagen, Inc.		
	A12	WO 2004/011440	02-05-2004	Banyu Pharmaceutical Co.		
	A13	WO 2004/056774	07-08-2004	Neurogen Corporation		
	A14	WO 03/049702	06-19-03	Amgen Inc.		

Examiner Signature	/Laura L. Stockton/
-----------------------	---------------------

Date	12/04/2008
------	------------

**Signature** \_\_\_\_\_ **Typed Name of Signatory** \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation 1 not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's check of citation designation number (optional). \*See Kinds Codes Form USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov). \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document: Use the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language translation is attached.

\_\_\_\_\_  
I hereby agree to obtain or attempt to obtain a benefit by the public which is in force (and by the

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IF YOU NEED ASSISTANCE IN COMPLETING THE FORM, CALL 1-800-PTO-9199 (1-800-786-9199) AND SELECT OPTION 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LLS/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 3**Complete if Known**

Application Number	10/554,036
Filing Date	October 20, 2005
First Named Inventor	Besidski
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	101023-1P US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A15	FREY, C. et al., "Iminoindolinone metal complexes, method for...high-molecular-weight material...containing such a metal complex," & EP, 23889, 19810211, accessn 1981:444733 <b>ABSTRACT ONLY</b>	
	A16	MILLER, R. et al., "Schistosoma mansoni: salicylanilides... cercarial penetration of mice," & Experimental Parasitology, 61(3), ppg. 359-68, 1956, accession no. 1986:472101	
	A17	PORTNAYA, B. et al., "Azomethine dyes. IV. Indoaniline...heterocyclic N-substituted 1-hydroxy-2-naphthamides," & Ts. Vses. Nauchn.-Issled. Kinnofotoinst. (No. 40) 106-18, 1960 <b>ABSTRACT ONLY</b>	
	A18	SHINKAI, H. et al., "Preparation of amide derivatives as nociception antagonists," & WO, A1, 9948492, 19990930, pp. 113, accession no. 1999:626041	
	A19	SUZUKI, N. et al., "Preparation of imidazole derivatives as gonadotropinreleasing hormone antagonists," & JP, A2, 2000095767, 20000404, pp. 79, accession no. 132:265201	
	A20	CHEMCATS, Accession No. 2001:53212, 24 April 2003, 3-Pyridinecarboxamide,N-(2-methyl-5-benzothiazolyl), CASRN 302953-34-0	
	A21	WILLITZER, H. et al., "Synthesis and antiviral activity of substituted 5-ureido- and 5-thioureidobenzimidazole derivatives," & Pharmazie, 33(1), 30-8, 1978	
	A22	Caterina, M.J., Schumacher, M.A., et al., Nature 1997 vol. 389, pgs 816 - 824	
	A23	Tominaga, M., Caterina, M.J., et al., Neuron 1998, vol. 21 pgs 531 - 543	
	A24	Walker, et al., J. Pharmacol Exp Ther. 2003 Jan; 304(1):56-62	

Examiner Signature	/Laura L. Stockton/	Date Considered	12/04/2008
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //LS/

Receipt date: 03/17/2006

10554036 - GAU: 1626

PTO/SB/083 (07-05)

Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number 10/554,036

Filing Date October 20, 2005

First Named Inventor Besidski

Art Unit Unknown

Examiner Name Unknown

Attorney Docket Number 101023-1P US

Sheet 2 of 4

of

2

4

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A25	Rashid, et al, J Pharmacol Exp Ther. 2003 March;304(3):940-948	
	A26	Hwang and Oh Curr Opin Pharmacol 2002 June; 2(3):235-242	
	A27	Yiangou, et al BJU Int 2001 June; 87(9): 774-779, Szallasi Am J Clin Pathol 2002 118: 110-121	
	A28	STN International, Caplus Acces No. 2004:101143, document no. 140:146168, Moriya, Minoru, et al; "Antagonist of ... Active Ingredient", & WO, A1, 2004011440, 20040205, 112	
	A29	STN International File Registry, January 2001 July 30, 2004	
	A30	Mark E. McDonnell, et al.; Bioorganic & Medicinal Chemistry Letters 14 (2004); pages 531-534	

Examiner  
Signature

/Laura L. Stockton/

Date  
Considered

12/04/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LLS/